Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $135,103.36 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 5,936 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $22.76, for a total value of $135,103.36. Following the completion of the sale, the insider directly owned 127,535 shares of the company’s stock, valued at approximately $2,902,696.60. The trade was a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 3.4%

KMTS stock opened at $25.06 on Thursday. Kestra Medical Technologies, Ltd. has a 1-year low of $14.10 and a 1-year high of $30.00. The business’s 50 day simple moving average is $22.78 and its 200 day simple moving average is $22.52. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.47 billion, a PE ratio of -10.36 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million for the quarter. As a group, research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Wall Street Analyst Weigh In

KMTS has been the subject of a number of research reports. The Goldman Sachs Group cut their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Oppenheimer assumed coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating for the company. Finally, Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.83.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KMTS. Price T Rowe Associates Inc. MD lifted its position in Kestra Medical Technologies by 137.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the period. Brown Advisory Inc. increased its holdings in Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after buying an additional 428,996 shares during the period. Alliancebernstein L.P. raised its position in shares of Kestra Medical Technologies by 13.7% in the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after buying an additional 179,885 shares in the last quarter. Eventide Asset Management LLC lifted its holdings in shares of Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the period. Finally, Franklin Resources Inc. boosted its position in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after acquiring an additional 612,343 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.